2024-10-11 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes a broad portfolio of innovative medicines.

**Performance Summary:**

* **Return:** AbbVie has outperformed the S&P 500 (VOO) with a cumulative return of 153.13% compared to the S&P 500's 134.82%.  This represents a 20.6% outperformance. Its relative outperformance rank, however, is at the 61.74th percentile, meaning it has performed better than 61.74% of its historical performance range. 
* **Recent Price Action:** 
    * **Closing Price:** $194.75
    * **5-day Moving Average:** $194.22
    * **20-day Moving Average:** $194.27
    * **60-day Moving Average:** $191.04
    * The price is currently trading above all three moving averages, suggesting a bullish trend.

**Technical Indicators:**

* **RSI:** 54.09, suggesting neither overbought nor oversold conditions.
* **PPO:** -0.14, suggesting potential for a downside correction.
* **Delta_Previous_Relative_Divergence:** -11.39, indicating a recent downward trend in relative outperformance compared to the S&P 500.
* **Expected Return:** 7.64%, representing the potential for upside over the next 5 years compared to the S&P 500.

**Earnings Analysis:**

AbbVie consistently exceeded earnings expectations in recent quarters. 

| Date     | EPS | Expected EPS |
|----------|-----|--------------|
| 2024-07-25 | 2.65 | 2.57        |
| 2024-04-26 | 2.31 | 2.26        |
| 2024-02-02 | 2.79 | 2.76        |
| 2023-10-27 | 2.95 | 2.86        |
| 2023-07-27 | 2.91 | 2.79        |

The most recent earnings report shows a strong performance, exceeding expectations by 3.1%.

**News & Recent Developments:**

**Market Outlook:** AbbVie's stock performance remains strong, with recent gains attributed to positive earnings reports and its robust pipeline. However, analysts are closely watching its patent expirations and potential impact on future growth.

**Analyst Opinions:** Many analysts maintain a bullish outlook on AbbVie due to its diversified portfolio of established and emerging drugs, its strong financial position, and its ongoing commitment to research and development. While some concerns exist regarding patent cliffs and potential competition, AbbVie's continued focus on innovation is expected to drive future growth.

**Performance Highlights:** 

* AbbVie's Humira biosimilar competition is a significant concern for investors, as it could impact sales. However, the company is aggressively pursuing new growth drivers, including Rinvoq and Skyrizi, which have the potential to offset some of the losses.
* The company has a robust pipeline of promising drugs in development, including treatments for immunology, oncology, and neuroscience. 

**Overall Analysis:**

AbbVie remains a strong performer in the pharmaceutical sector, despite facing some headwinds related to patent expirations and biosimilar competition. The company's commitment to innovation, strong earnings record, and robust pipeline suggest continued growth potential in the long term. Investors should monitor the impact of biosimilar competition on Humira sales, but AbbVie's new drug launches and robust pipeline provide opportunities for future growth. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Investors are advised to conduct their own due diligence before making any investment decisions.